Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

EyePoint Pharmaceuticals (EYPT) Common Equity: 2010-2018

Historic Common Equity for EyePoint Pharmaceuticals (EYPT) over the last 9 years, with Jun 2018 value amounting to $11.7 million.

  • EyePoint Pharmaceuticals' Common Equity rose 142.46% to $19.9 million in Q1 2019 from the same period last year, while for Mar 2019 it was $19.9 million, marking a year-over-year increase of 142.46%. This contributed to the annual value of $11.7 million for FY2018, which is 12.37% down from last year.
  • Latest data reveals that EyePoint Pharmaceuticals reported Common Equity of $11.7 million as of FY2018, which was down 12.37% from $13.3 million recorded in FY2017.
  • In the past 5 years, EyePoint Pharmaceuticals' Common Equity registered a high of $23.4 million during FY2015, and its lowest value of $11.7 million during FY2018.
  • In the last 3 years, EyePoint Pharmaceuticals' Common Equity had a median value of $13.3 million in 2017 and averaged $15.3 million.
  • In the last 5 years, EyePoint Pharmaceuticals' Common Equity soared by 93.82% in 2014 and then tumbled by 36.13% in 2017.
  • Over the past 5 years, EyePoint Pharmaceuticals' Common Equity (Yearly) stood at $14.9 million in 2014, then soared by 56.58% to $23.4 million in 2015, then decreased by 10.64% to $20.9 million in 2016, then tumbled by 36.13% to $13.3 million in 2017, then declined by 12.37% to $11.7 million in 2018.